AU2017345390B2 - Use of itolizumab to reduce phosphorylation of CD6 - Google Patents

Use of itolizumab to reduce phosphorylation of CD6 Download PDF

Info

Publication number
AU2017345390B2
AU2017345390B2 AU2017345390A AU2017345390A AU2017345390B2 AU 2017345390 B2 AU2017345390 B2 AU 2017345390B2 AU 2017345390 A AU2017345390 A AU 2017345390A AU 2017345390 A AU2017345390 A AU 2017345390A AU 2017345390 B2 AU2017345390 B2 AU 2017345390B2
Authority
AU
Australia
Prior art keywords
ser
leu
val
thr
itolizumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017345390A
Other languages
English (en)
Other versions
AU2017345390A1 (en
Inventor
Usha BUGHANI
Ramakrishnan Melarkode
Pradip Nair
Ravindra Belavinakodige Sadashivarao
Arindam Saha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocon Ltd
Original Assignee
Biocon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd filed Critical Biocon Ltd
Publication of AU2017345390A1 publication Critical patent/AU2017345390A1/en
Application granted granted Critical
Publication of AU2017345390B2 publication Critical patent/AU2017345390B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Electrically Operated Instructional Devices (AREA)
AU2017345390A 2016-10-18 2017-10-16 Use of itolizumab to reduce phosphorylation of CD6 Active AU2017345390B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201641035602 2016-10-18
IN201641035602 2016-10-18
PCT/IB2017/056403 WO2018073721A1 (en) 2016-10-18 2017-10-16 Use of itolizumab to reduce phosphorylation of cd6

Publications (2)

Publication Number Publication Date
AU2017345390A1 AU2017345390A1 (en) 2019-05-02
AU2017345390B2 true AU2017345390B2 (en) 2024-08-08

Family

ID=62019244

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017345390A Active AU2017345390B2 (en) 2016-10-18 2017-10-16 Use of itolizumab to reduce phosphorylation of CD6

Country Status (8)

Country Link
US (2) US20190248913A1 (cg-RX-API-DMAC10.html)
EP (1) EP3528846A4 (cg-RX-API-DMAC10.html)
JP (1) JP7065085B2 (cg-RX-API-DMAC10.html)
KR (1) KR102469798B1 (cg-RX-API-DMAC10.html)
AU (1) AU2017345390B2 (cg-RX-API-DMAC10.html)
CA (1) CA3076861A1 (cg-RX-API-DMAC10.html)
IL (1) IL266087B2 (cg-RX-API-DMAC10.html)
WO (1) WO2018073721A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
WO2019169015A1 (en) * 2018-02-27 2019-09-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma
US20230076643A1 (en) * 2019-12-30 2023-03-09 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2993186T (pt) * 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
US10189899B2 (en) * 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
KR102514528B1 (ko) * 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A IRA ET AL.: "Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti- CD 6 itolizumab", MABS, vol. 6, no. 3, 1 May 2014 (2014-05-01), pages 782 - 792, XP055478453 *
Krupashankar et al., Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study,2014. *
Rodriguez, P. C et al., A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis, Results in Immunology, Volume 2, 2012, Pages 204-211 *

Also Published As

Publication number Publication date
KR102469798B1 (ko) 2022-11-22
KR20190070957A (ko) 2019-06-21
EP3528846A1 (en) 2019-08-28
EP3528846A4 (en) 2020-06-03
US20190248913A1 (en) 2019-08-15
WO2018073721A1 (en) 2018-04-26
AU2017345390A1 (en) 2019-05-02
IL266087B1 (en) 2023-10-01
IL266087B2 (en) 2024-02-01
US20240101700A1 (en) 2024-03-28
JP2020504597A (ja) 2020-02-13
JP7065085B2 (ja) 2022-05-11
IL266087A (en) 2019-06-30
CA3076861A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
US20240101700A1 (en) Use of itolizumab to reduce phosphorylation of cd6
US20220193199A1 (en) Il-15 and il-15ralpha sushi domain based modulokines
JP2022091985A (ja) 組合せ医薬組成物
JP4938957B2 (ja) Cd30またはcd30lのアンタゴニストを使用する自己免疫および慢性炎症性状態の処置法
KR102040235B1 (ko) RGMa 결합 단백질 및 그 사용
US11547741B2 (en) Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies
Bloemendaal et al. Anti–tumor necrosis factor with a glyco-engineered Fc-region has increased efficacy in mice with colitis
KR20230015348A (ko) Th2 개재성 질환을 치료 또는 예방하기 위한 PD-1 작용제 함유 의약 조성물
RU2832188C2 (ru) Дозировка и схема введения для лечения или предупреждения связанных с с5 заболеваний посредством применения антитела против с5 кровалимаба
RU2817602C2 (ru) Молекулы антител, которые связывают cd137 и ox40
HK40072257A (en) A PHARMACEUTICAL COMBINATION COMPRISING A BIFUNCTIONAL IMMUNE CHECKPOINT/TGFβ INHIBITOR
HK40074884A (en) Il-15 and il-15ralpha sushi domain based on modulokines
HK40004449A (en) Il-15 and il-15raplha sushi domain based modulokines
HK40024980A (en) Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies
HK40004449B (en) Il-15 and il-15ralpha sushi domain based modulokines
Levin et al. Therapeutic efficacy of anti-TNF is mediated via Fcγ-receptors and Fc glyco-engineering increases therapeutic potency

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)